HIV

Young adults with HIV who experience financial instability are significantly more likely to struggle with adhering to antiretroviral therapy, highlighting how economic hardship can directly impact treatment success.

Michael Chancley Jr.’s personal experience with PrEP informs his work at PrEP4All as he advocates for expanded access and equity in HIV prevention amid persistent stigma, provider misinformation and stark racial and gender disparities in PrEP uptake.

The FDA has approved Merck’s once-daily single-tablet HIV treatment Idvynso (doravirine/islatravir) for virologically suppressed adults, based on phase 3 trials showing high rates of maintained viral suppression and generally manageable safety outcomes.

Julie Kendle, Pharm.D., senior director of clinical pharmacy at IPD Analytics, explains the evolution of HIV PrEP from daily oral medications to long-acting injectables and how health policy and payer strategies can improve access, adherence and outcomes.

Nearly all U.S. adolescents who are at risk for HIV are missing out on preexposure prophylaxis, with significant disparities in access based on age, gender and geographic location.

Doctors Without Borders has accused Gilead of restricting access to its HIV prevention drug lenacapavir by refusing humanitarian sales and limiting supply, arguing this is hindering global efforts to expand HIV prevention in high-need regions.

In this conversation, Kirk Grisham, M.P.H., and Vishakh Unnikrishnan, M.P.H., both from the Center for HIV and Infectious Disease Policy at the O’Neill Institute, explain how federal funding cuts are destabilizing state HIV programs and why state leadership and political will now largely determine whether people keep access to HIV prevention and care.

In Florida, abrupt cuts to HIV medication and insurance support are forcing patients off trusted regimens, exposing dangerous coverage gaps, and illustrating how policy decisions can quietly drive up both human and financial costs in the U.S. healthcare system.

A study published in Substance Use and Addiction found that combining nicotine replacement therapy with a rewards-based contingency management program helped people with HIV achieve higher short-term smoking cessation rates than nicotine replacement therapy alone.

Florida has reduced funding and tightened eligibility for its AIDS Drug Assistance Program, limiting access to the widely used HIV medication Biktarvy for thousands of patients, while more than 20 other states consider similar cuts amid rising program costs and stagnant federal funding.

Researchers highlighted the anti-inflammatory benefits of GLP-1 receptor agonists in people with HIV, plus a growing concern over rising STI rates and the cautious promise of doxycycline post-exposure prophylaxis as a partial prevention strategy.

ViiV Healthcare unveiled new data at the Conference on Retroviruses and Opportunistic Infections on next-generation long-acting HIV therapies.

An abstract presented at CROI 2026 found that continuous Medicaid coverage during the COVID-19 public health emergency was associated with decreased dependence on AIDS Drug Assistance Programs.

Zimbabwe has become one of the first countries in the world to launch a national lenacapavir program, introducing the twice-yearly injectable HIV prevention drug as part of its ongoing efforts to reduce new infections and end AIDS as a public health threat.

Florida’s planned AIDS Drug Assistance Program cuts could strip more than 16,000 people of life-saving HIV medications, a move Colleen Kelley, M.D., M.P.H., warns will increase illness, deaths and HIV transmission while sowing fear among already vulnerable patients.

Adolescent and young women are far less likely than men to receive HIV prevention medication despite meeting clinical eligibility and facing substantial HIV risk.

In this interview, Emma Kaplan-Lewis, M.D., clinical quality director for HIV, hepatitis and sexual health services at NYC Health + Hospitals, discusses the results of her latest case study on PrEP uptake and why it’s important to “celebrate success.”

In 2024, 91% of patients receiving care through the Ryan White HIV/AIDS Program were virally suppressed, underscoring the program’s role in improving HIV outcomes.

Alexa B. D’Angelo, Ph.D., M.P.H. and Jeremiah Johnson share their predictions for HIV challenges in 2026.

World AIDS Day highlights ongoing challenges in HIV prevention and treatment, urging renewed commitment to end the epidemic and support affected communities.

Nicotine dependency is a worldwide health threat, especially for HIV patients, who are more likely to smoke and to have health complications than healthy patients.

Medicaid expansion increased overall PrEP access in the U.S., but significant racial, gender and structural disparities persist, limiting equitable HIV prevention despite rising national uptake.

The investigational lenacapavir-bictegravir tablet has the potential to reduce the pill burden of HIV treatment, according to a recent news release.

In a historical public health move, the Maldives has eliminated mother-to-child HIV, syphilis and hepatitis B, which are collectively responsible for millions of deaths annually across the globe.

More than 60 abstracts will be presented from the ViiV portfolio, including updates from the phase 1 crossover study, the first comparing the acceptability and tolerability of long acting cabotegravir and lenacapavir injections after a single dose.